Oppenheimer & Co’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.66M | Sell |
2,962
-290
| -9% | -$186K | 0.02% | 660 |
|
|
2025
Q4 | $2.2M | Buy |
3,252
+2,428
| +295% | +$1.65M | 0.03% | 523 |
|
|
2025
Q3 | $526K | Buy |
824
+46
| +6% | +$27.9K | 0.01% | 1154 |
|
|
2025
Q2 | $417K | Sell |
778
-58
| -7% | -$27.7K | 0.01% | 1210 |
|
|
2025
Q1 | $351K | Hold |
836
| – | – | 0.01% | 1202 |
|
|
2024
Q4 | $346K | Sell |
836
-80
| -9% | -$35.1K | 0.01% | 1201 |
|
|
2024
Q3 | $463K | Hold |
916
| – | – | 0.01% | 1064 |
|
|
2024
Q2 | $446K | Buy |
916
+37
| +4% | +$18.6K | 0.01% | 1034 |
|
|
2024
Q1 | $475K | Sell |
879
-50
| -5% | -$27.3K | 0.01% | 1010 |
|
|
2023
Q4 | $516K | Sell |
929
-63
| -6% | -$29.6K | 0.01% | 957 |
|
|
2023
Q3 | $434K | Buy |
992
+2
| +0.2% | +$997 | 0.01% | 997 |
|
|
2023
Q2 | $497K | Buy |
990
+34
| +4% | +$16.3K | 0.01% | 973 |
|
|
2023
Q1 | $478K | Sell |
956
-169
| -15% | -$80.9K | 0.01% | 957 |
|
|
2022
Q4 | $459K | Sell |
1,125
-470
| -29% | -$182K | 0.01% | 938 |
|
|
2022
Q3 | $519K | Buy |
1,595
+53
| +3% | +$19.5K | 0.01% | 885 |
|
|
2022
Q2 | $540K | Sell |
1,542
-4,677
| -75% | -$1.91M | 0.01% | 889 |
|
|
2022
Q1 | $3.4M | Sell |
6,219
-919
| -13% | -$483K | 0.06% | 360 |
|
|
2021
Q4 | $4.7M | Sell |
7,138
-8,045
| -53% | -$5.05M | 0.08% | 285 |
|
|
2021
Q3 | $9.44M | Sell |
15,183
-20,391
| -57% | -$13.7M | 0.18% | 122 |
|
|
2021
Q2 | $22.5M | Buy |
35,574
+1,585
| +5% | +$875K | 0.4% | 39 |
|
|
2021
Q1 | $16.6M | Buy |
33,989
+11,505
| +51% | +$5.76M | 0.33% | 57 |
|
|
2020
Q4 | $11.2M | Buy |
22,484
+2,129
| +10% | +$953K | 0.24% | 91 |
|
|
2020
Q3 | $8M | Buy |
20,355
+943
| +5% | +$349K | 0.2% | 108 |
|
|
2020
Q2 | $6.41M | Sell |
19,412
-510
| -3% | -$148K | 0.17% | 125 |
|
|
2020
Q1 | $4.83M | Sell |
19,922
-7,621
| -28% | -$1.99M | 0.15% | 147 |
|
|
2019
Q4 | $7.19M | Buy |
27,543
+3,053
| +12% | +$805K | 0.18% | 123 |
|
|
2019
Q3 | $6.66M | Buy |
24,490
+1,312
| +6% | +$365K | 0.18% | 128 |
|
|
2019
Q2 | $6.38M | Buy |
23,178
+5,744
| +33% | +$1.42M | 0.17% | 129 |
|
|
2019
Q1 | $3.9M | Buy |
17,434
+321
| +2% | +$66.3K | 0.1% | 223 |
|
|
2018
Q4 | $3.18M | Buy |
17,113
+14,430
| +538% | +$2.96M | 0.1% | 225 |
|
|
2018
Q3 | $670K | Buy |
2,683
+83
| +3% | +$20.1K | 0.02% | 743 |
|
|
2018
Q2 | $567K | Buy |
2,600
+525
| +25% | +$108K | 0.02% | 813 |
|
|
2018
Q1 | $397K | Sell |
2,075
-189
| -8% | -$34.9K | 0.01% | 941 |
|
|
2017
Q4 | $354K | Sell |
2,264
-150
| -6% | -$23.6K | 0.01% | 991 |
|
|
2017
Q3 | $375K | Sell |
2,414
-17,088
| -88% | -$2.7M | 0.01% | 951 |
|
|
2017
Q2 | $3.15M | Buy |
19,502
+2,129
| +12% | +$346K | 0.09% | 282 |
|
|
2017
Q1 | $2.69M | Buy |
+17,373
| New | +$2.39M | 0.08% | 308 |
|
|
2016
Q2 | – | Sell |
-3,230
| Closed | -$253K | – | 1264 |
|
|
2016
Q1 | $253K | Sell |
3,230
-9,285
| -74% | -$669K | 0.01% | 1006 |
|
|
2015
Q4 | $913K | Sell |
12,515
-365
| -3% | -$26K | 0.03% | 580 |
|
|
2015
Q3 | $957K | Buy |
12,880
+980
| +8% | +$70.2K | 0.03% | 592 |
|
|
2015
Q2 | $763K | Buy |
11,900
+2,100
| +21% | +$145K | 0.02% | 709 |
|
|
2015
Q1 | $756K | Sell |
9,800
-370
| -4% | -$28.8K | 0.02% | 716 |
|
|
2014
Q4 | $754K | Sell |
10,170
-112
| -1% | -$7.85K | 0.02% | 697 |
|
|
2014
Q3 | $606K | Buy |
10,282
+3,780
| +58% | +$239K | 0.02% | 775 |
|
|
2014
Q2 | $433K | Hold |
6,502
| – | – | 0.01% | 903 |
|
|
2014
Q1 | $396K | Sell |
6,502
-188
| -3% | -$11.2K | 0.01% | 917 |
|
|
2013
Q4 | $355K | Hold |
6,690
| – | – | 0.01% | 950 |
|
|
2013
Q3 | $333K | Buy |
+6,690
| New | +$322K | 0.01% | 927 |
|
Other funds holding IDXX
VCM
VPM
Oppenheimer & Co's IDXX Position: Q1 2026 in Review
Oppenheimer & Co reduced its Idexx Laboratories (IDXX) stake by 8.9% in Q1 2026, selling an estimated $186K and leaving 2,962 shares worth $1.66M. The position accounts for 0.02% of the portfolio, ranked #660.
Oppenheimer & Co first reported a position in IDXX in Q3 2013 and has held it in 48 quarters since. The position peaked at $22.5M in Q2 2021. 1,312 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Oppenheimer & Co held 2,962 shares of Idexx Laboratories worth $1.66M as of Q1 2026.
- Oppenheimer & Co sold 290 Idexx Laboratories shares in Q1 2026, an estimated $186K.
- Idexx Laboratories made up 0.02% of Oppenheimer & Co's portfolio in Q1 2026, its #660 holding.
- Oppenheimer & Co first reported a position in Idexx Laboratories in Q3 2013 and has held it in 48 quarters since.
- Oppenheimer & Co's Idexx Laboratories position peaked at $22.5M in Q2 2021.
- 1,312 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.